Praxis Precision Medicines 

Yahoo Finance • 13 days ago

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

On May 15, 2026, HighVista Strategies disclosed it sold 70,503 shares of Maze Therapeutics(NASDAQ:MAZE) in Q1 2026, an estimated $3.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange... Full story

Yahoo Finance • 13 days ago

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

On May 15, 2026, HighVista Strategies disclosed a purchase of 96,218 shares of Tyra Biosciences(NASDAQ:TYRA), estimated at $3.11 million based on quarterly average pricing. What happened According to its SEC filing dated May 15, 2026, Hi... Full story

Yahoo Finance • 13 days ago

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics(NASDAQ:VRDN) in its May 15, 2026, SEC filing, an estimated $7.08 million trade based on quarterly average pricing. What happened According to a SEC filing da... Full story

Yahoo Finance • 13 days ago

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally

On May 15, 2026, Cormorant Asset Management disclosed a new position in Dianthus Therapeutics(NASDAQ:DNTH), acquiring 950,000 shares in an estimated $55.01 million trade based on quarterly average pricing. What happened According to a Se... Full story

Yahoo Finance • 13 days ago

Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More

Key Points Cormorant Asset Management bought 5,800,000 Erasca shares in the first quarter, an estimated $68.55 million trade based on quarterly average pricing. The quarter-end position value rose by $93.84 million, reflecting both share... Full story

Yahoo Finance • 14 days ago

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy

What happened According to an SEC filing dated May 15, 2026, Acuta Capital Partners, LLC initiated a new position in Erasca(NASDAQ:ERAS) during the first quarter. The fund acquired 354,575 shares, with an estimated transaction value of $4... Full story

Yahoo Finance • 23 days ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic encep... Full story

Yahoo Finance • last month

Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 best biotech stocks with highest upside potential. As of the close of play on April 24, the broader consensus sentiments towards Praxis Precision Medicines Inc. (NASDAQ:PRAX)... Full story

Yahoo Finance • last month

Praxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in Neurology

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Praxis Precision Medicines, Inc. (NASDAQ:PRAX) ranks 1st on this list. Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is still pre-revenue but Wal... Full story

Yahoo Finance • last month

Praxis Precision Medicines (PRAX): One of the Best Upside Stocks

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 9 Best Upside Stocks to Buy According to Analysts. Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best upside stocks to buy according to analysts. On April 14, Prax... Full story

Yahoo Finance • last month

Hims & Hers (HIMS) Jumps 48% Ahead of Earnings

Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stocks With Monster Returns. Hims & Hers saw its share prices jump by 48.3 percent week-on-week as investors positioned portfolios ahead of the results of its earnings performance for t... Full story

Yahoo Finance • 2 months ago

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous sy... Full story

Yahoo Finance • 2 months ago

Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the 10 Stocks Investors Are Buying Now. Sarepta Therapeutics soared by 34.98 percent on Wednesday to finish at $23.77 apiece, as investors took path from Morgan Stanley’s 25-percent price... Full story

Yahoo Finance • 2 months ago

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges

On February 17, 2026, B Group, Inc. disclosed a new position in Structure Therapeutics(NASDAQ:GPCR), acquiring 90,000 shares in the fourth quarter. What happened B Group disclosed in a Securities and Exchange Commission (SEC) filing date... Full story

Yahoo Finance • 2 months ago

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

Key Points Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter. The value of the position was $68.75 million at quarter-end. The new position places Olema outside... Full story

Yahoo Finance • 2 months ago

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant(NASDAQ:IMVT), an estimated $24.53 million trade based on quarterly average pricing. Lo... Full story

Yahoo Finance • 3 months ago

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

Key Points Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new... Full story

Yahoo Finance • 3 months ago

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline

On February 17, 2026, Deerfield Management Company disclosed a buy of Praxis Precision Medicines(NASDAQ:PRAX), adding 62,500 shares in a trade estimated at $11.64 million based on quarterly average pricing. What happened According to a f... Full story

Yahoo Finance • 3 months ago

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough

On February 17, 2026, Driehaus Capital Management disclosed a buy of Xenon Pharmaceuticals(NASDAQ:XENE), adding 369,577 shares in an estimated $15.52 million trade based on quarterly average pricing. What happened According to an SEC fil... Full story

Yahoo Finance • 3 months ago

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know

Driehaus Capital Management disclosed a significant buy of Eos Energy Enterprises(NASDAQ:EOSE) in its February 17, 2026, SEC filing, adding 7.70 million shares in an estimated $110.72 million trade based on quarterly average pricing. What... Full story